Gefitinib Unknown Status Phase 2 / 3 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT02319577GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
NCT01833572Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
NCT01784549Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease
NCT01755923Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
NCT01746277Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
NCT01510990First Line Gefitinib by FDG-PET Metabolic Response
NCT00319800Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
NCT01312337Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)